ICS and COPD: Time to clear the air
Paul A Ford, Richard EK Russell, Peter J Barnes
Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK
The debate about what constitutes the correct treatment for COPD has recently intensified. This discussion has grumbled on ever since the first multicenter trials using inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) such as the European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP) and Inhaled Steroids in Obstructive Lung Disease (ISOLDE) were published in the late 1990’s and the results of trials such as TORCH (TOwards a Revolution in COPD Health) using combination products has only added to the confusion.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]